De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Apellis Pharmaceuticals Toekomstige groei

Future criteriumcontroles 6/6

Apellis Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 69.6% en 22.8% per jaar. De winst per aandeel zal naar verwachting groeien met 69.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 380.3% zijn.

Belangrijke informatie

69.7%

Groei van de winst

69.4%

Groei van de winst per aandeel

Biotechs winstgroei	35.0%
Inkomstengroei	22.9%
Toekomstig rendement op eigen vermogen	380.3%
Dekking van analisten	Good
Laatst bijgewerkt	17 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:1JK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,390	253	305	144	17
12/31/2025	1,022	-2	56	46	19
12/31/2024	787	-168	-190	-163	19
6/30/2024	629	-333	-409	-408	N/A
3/31/2024	524	-417	-551	-550	N/A
12/31/2023	397	-529	-596	-595	N/A
9/30/2023	273	-606	-639	-638	N/A
6/30/2023	185	-657	-625	-623	N/A
3/31/2023	106	-691	-582	-580	N/A
12/31/2022	75	-652	-515	-514	N/A
9/30/2022	113	-634	-486	-485	N/A
6/30/2022	97	-638	-501	-500	N/A
3/31/2022	81	-702	-522	-521	N/A
12/31/2021	67	-746	-564	-563	N/A
9/30/2021	256	-520	-310	-309	N/A
6/30/2021	251	-460	-245	-240	N/A
3/31/2021	251	-360	-211	-205	N/A
12/31/2020	251	-345	-166	-160	N/A
9/30/2020	1	-536	-389	-385	N/A
6/30/2020	N/A	-470	-340	-338	N/A
3/31/2020	N/A	-423	-285	-284	N/A
12/31/2019	N/A	-305	-213	-211	N/A
9/30/2019	N/A	-228	-175	-174	N/A
6/30/2019	N/A	-194	-154	-153	N/A
3/31/2019	N/A	-156	-145	-144	N/A
12/31/2018	N/A	-128	-131	-131	N/A
9/30/2018	N/A	-109	-102	-102	N/A
6/30/2018	N/A	-85	-80	-80	N/A
3/31/2018	N/A	-64	N/A	-61	N/A
12/31/2017	N/A	-51	N/A	-47	N/A
9/30/2017	N/A	-39	N/A	-38	N/A
6/30/2017	N/A	-35	N/A	-33	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-27	N/A	-26	N/A
9/30/2016	N/A	-29	N/A	-27	N/A
6/30/2016	N/A	-53	N/A	-24	N/A
3/31/2016	N/A	-50	N/A	-21	N/A
12/31/2015	N/A	-47	N/A	-19	N/A
9/30/2015	N/A	-41	N/A	-14	N/A
6/30/2015	N/A	-12	N/A	-14	N/A
3/31/2015	N/A	-12	N/A	-12	N/A
12/31/2014	N/A	-11	N/A	-10	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat 1JK de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 0.8% ).

Winst versus markt: Er wordt verwacht dat 1JK de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat 1JK binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van 1JK ( 22.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van 1JK ( 22.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 1JK zal naar verwachting over 3 jaar zeer hoog zijn ( 380.3 %).

Apellis Pharmaceuticals Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Forecast breakeven date pushed back to 2026

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Forecast to breakeven in 2025

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023)

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

New 90-day high: €41.40

Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

Apellis Pharmaceuticals Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH

New 90-day high: €31.20

Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US